Spotting: Labs, Diagnosis, and Next Steps

What Spotting Actually Means in Clinical Terms

Spotting refers to light vaginal bleeding that occurs outside the expected menstrual period. The International Federation of Gynecology and Obstetrics (FIGO) classifies it under the broader term abnormal uterine bleeding (AUB), using the PALM-COEIN system to categorize causes as either structural or non-structural [1]. This distinction drives every diagnostic and treatment decision that follows.

Intermenstrual bleeding differs from heavy menstrual bleeding (menorrhagia) and from postcoital bleeding, though these patterns can overlap. A 2011 FIGO consensus defined normal cycle parameters: frequency of 24 to 38 days, duration of 4.5 to 8 days, and volume up to 80 mL per cycle [1]. Any bleeding outside those boundaries qualifies as abnormal. The clinical significance ranges from benign (a skipped ovulation) to urgent (endometrial hyperplasia or malignancy). Your provider's job is to determine where on that spectrum you fall, and the workup starts with a structured lab panel paired with targeted imaging.

The PALM-COEIN acronym itself is worth understanding. PALM covers structural causes: Polyp, Adenomyosis, Leiomyoma (fibroids), and Malignancy/hyperplasia. COEIN covers non-structural causes: Coagulopathy, Ovulatory dysfunction, Endometrial factors, Iatrogenic causes, and Not yet classified [1]. Knowing which category your spotting falls into shapes the entire treatment plan.

Why You Might Be Spotting: The Major Causes

Ovulatory dysfunction is the single most common explanation for spotting in reproductive-age women, particularly at the extremes of reproductive life. In adolescents, the hypothalamic-pituitary-ovarian (HPO) axis takes 2 to 5 years after menarche to mature, producing irregular cycles and breakthrough bleeding in up to 50% of teens during the first gynecologic year [2]. In perimenopausal women (typically ages 40 to 55), declining ovarian reserve leads to erratic estrogen and progesterone levels that destabilize the endometrial lining.

Hormonal contraceptives cause breakthrough bleeding in 30% to 50% of new users during the first one to three months [3]. This applies across formulations: combined oral contraceptives, progestin-only pills, the levonorgestrel IUD, the etonogestrel implant, and depot medroxyprogesterone acetate (DMPA). The mechanism involves endometrial atrophy and fragile superficial vessels that rupture under low-dose hormonal support. Missing pills or inconsistent timing amplifies the effect.

Structural lesions represent the second broad category. Endometrial polyps are found in 10% to 40% of women investigated for AUB, depending on the population studied and imaging method used [4]. Uterine fibroids (leiomyomas) affect up to 70% of women by age 50, with submucosal fibroids being the subtype most likely to cause intermenstrual bleeding because they distort the uterine cavity [5]. Adenomyosis, where endometrial glands invade the myometrium, produces both heavy periods and intermenstrual spotting.

Less common but clinically important causes include cervical ectropion, cervicitis (often from chlamydia or gonorrhea infection), endometrial hyperplasia, and endometrial cancer. The American College of Obstetricians and Gynecologists (ACOG) notes that endometrial cancer accounts for approximately 1% to 2% of AUB cases in premenopausal women, but that percentage rises with age and in the presence of risk factors like obesity, unopposed estrogen exposure, or tamoxifen use [6].

Coagulopathies deserve mention. Von Willebrand disease affects roughly 1% of the general population, but prevalence among women presenting with heavy menstrual bleeding may reach 13% according to a systematic review published in the American Journal of Obstetrics and Gynecology [7]. Thrombocytopenia, platelet function disorders, and anticoagulant medications also produce intermenstrual bleeding.

The Lab Panel Your Doctor Should Order

A pregnancy test comes first. Always. A serum beta-hCG rules out pregnancy, ectopic pregnancy, and gestational trophoblastic disease before any other workup proceeds [6]. This is non-negotiable regardless of reported contraceptive use or sexual history.

The complete blood count (CBC) serves two purposes: it quantifies anemia from chronic blood loss (hemoglobin below 12 g/dL in women) and flags thrombocytopenia or other hematologic abnormalities that could explain the bleeding. Ferritin should be added if the hemoglobin is low-normal, since iron deficiency precedes overt anemia by months [8].

Thyroid function testing (TSH) is standard because both hypothyroidism and hyperthyroidism disrupt menstrual regularity. The American Thyroid Association reports that thyroid dysfunction affects up to 5% of women of reproductive age, and subclinical hypothyroidism (TSH 4.5 to 10 mIU/L) can produce anovulation and spotting [9].

Prolactin levels should be checked when cycles are irregular or absent. Hyperprolactinemia suppresses GnRH pulsatility, leading to anovulation. Causes range from pituitary microadenomas to medications (antipsychotics, metoclopramide, SSRIs).

Coagulation screening (PT, aPTT, and von Willebrand panel) is indicated when bleeding has been heavy since menarche, when there is a family history of bleeding disorders, or when bleeding is refractory to hormonal management. ACOG Practice Bulletin No. 128 recommends screening adolescents with heavy menstrual bleeding for underlying coagulopathies [6].

Additional labs based on clinical suspicion:

• Testosterone, DHEA-S, and 17-hydroxyprogesterone if polycystic ovary syndrome (PCOS) or congenital adrenal hyperplasia is suspected
• FSH and estradiol on cycle day 2 or 3 if diminished ovarian reserve is a concern
• Chlamydia and gonorrhea NAAT testing if cervicitis is present on exam
• HbA1c or fasting glucose in obese patients, since insulin resistance drives anovulation in PCOS [10]

Imaging and Procedures: What Comes After Labs

Transvaginal ultrasound (TVUS) is the first-line imaging study for evaluating abnormal uterine bleeding. It measures endometrial thickness, identifies polyps, characterizes fibroids by location (submucosal vs. intramural vs. subserosal), and detects signs of adenomyosis such as myometrial cysts and an asymmetric uterine wall [11]. In premenopausal women, endometrial thickness varies with the cycle phase, so TVUS is ideally performed in the early follicular phase (days 4 through 6) when the endometrium is thinnest and lesions are easier to detect.

Saline infusion sonohysterography (SIS) adds diagnostic precision. Instilling sterile saline into the uterine cavity during TVUS improves detection of intracavitary lesions. A meta-analysis in Obstetrics & Gynecology reported sensitivity of 95% and specificity of 88% for SIS in detecting endometrial polyps, compared to 58% sensitivity for standard TVUS alone [12]. If your provider suspects a polyp or submucosal fibroid but the baseline ultrasound is equivocal, SIS is the logical next step.

Endometrial biopsy is the definitive test for excluding hyperplasia and malignancy. ACOG recommends biopsy for all women aged 45 and older with AUB [6]. For women aged 35 to 44, biopsy is recommended when risk factors are present: obesity (BMI ≥30), chronic anovulation, tamoxifen use, or a family history of endometrial or colon cancer (Lynch syndrome). In women under 35, biopsy is reserved for those with persistent bleeding unresponsive to medical therapy or significant risk factors. The Pipelle device captures an adequate endometrial sample in an office setting with sensitivity exceeding 90% for detecting endometrial cancer [13].

Hysteroscopy provides direct visualization of the uterine cavity and allows simultaneous biopsy or resection of polyps and submucosal fibroids. It is typically reserved for cases where office biopsy is non-diagnostic, SIS shows an intracavitary lesion, or tissue diagnosis is needed before definitive management.

MRI is not a first-line study for spotting but becomes useful when adenomyosis needs to be distinguished from fibroids, when fibroid mapping is required before myomectomy, or when malignancy staging is necessary [11].

Treatment Based on the Diagnosis

Treatment for spotting depends entirely on the underlying cause identified through the workup above. There is no single "spotting treatment." The approach splits along the PALM-COEIN categories.

For ovulatory dysfunction (the most common cause): Combined hormonal contraceptives (estrogen plus progestin) regulate the endometrial lining and eliminate breakthrough bleeding in most cases. The Cochrane review on oral contraceptives for heavy menstrual bleeding found that combined pills reduced menstrual blood loss by 40% to 50% compared with baseline [14]. Cyclic progestins (medroxyprogesterone acetate 10 mg for 10 to 14 days per cycle) represent an alternative for women who cannot take estrogen. The levonorgestrel 52 mg IUD (Mirena) reduces menstrual blood loss by up to 90% at 12 months and is recommended by NICE as a first-line treatment for heavy menstrual bleeding in women who desire long-acting contraception [15].

For contraceptive-related spotting: Reassurance is the first intervention. Most breakthrough bleeding resolves by the third cycle of consistent use. If spotting persists beyond 3 months, options include switching to a higher-estrogen formulation (from 20 mcg to 30 to 35 mcg ethinyl estradiol), adding short-course supplemental estrogen (conjugated estrogen 1.25 mg or estradiol 2 mg for 7 days), or switching contraceptive methods entirely [3].

For endometrial polyps: Hysteroscopic polypectomy is the standard treatment. Polyps >1.5 cm, symptomatic polyps, and polyps in postmenopausal women warrant removal because of a 0.5% to 3% risk of harboring premalignant or malignant cells [4]. Small, asymptomatic polyps in premenopausal women may be observed with repeat imaging in 6 to 12 months.

For fibroids causing spotting: Management depends on fibroid size, location, number, and the patient's reproductive goals. Medical options include the levonorgestrel IUD, GnRH agonists (leuprolide) for short-term presurgical shrinkage, and the oral GnRH antagonist combination relugolix-estradiol-norethindrone (Myfembree), which the FDA approved in 2021 for heavy menstrual bleeding associated with uterine fibroids [16]. Surgical options include hysteroscopic myomectomy for submucosal fibroids, laparoscopic or abdominal myomectomy for larger or multiple fibroids, and uterine artery embolization as a minimally invasive alternative.

For endometrial hyperplasia without atypia: Progestin therapy (oral medroxyprogesterone acetate 10 to 20 mg daily, or the levonorgestrel IUD) for 3 to 6 months followed by repeat biopsy is the standard approach. The regression rate with the levonorgestrel IUD reaches 90% to 96% at 12 months in observational studies [17].

For hyperplasia with atypia or endometrial cancer: Referral to gynecologic oncology is required. Hysterectomy is the definitive treatment for atypical hyperplasia in women who have completed childbearing [6].

For coagulopathies: Treatment of the underlying bleeding disorder (desmopressin for von Willebrand disease type 1, factor replacement for other deficiencies) combined with hormonal management of the menstrual cycle. Tranexamic acid 1,300 mg three times daily during bleeding episodes reduces menstrual blood loss by 40% and was FDA-approved for heavy menstrual bleeding in 2009 [18].

When Spotting Requires Urgent Evaluation

Not every episode of spotting needs an emergency department visit. But certain patterns demand same-day or next-day evaluation.

Seek urgent care if spotting is accompanied by dizziness, lightheadedness, or tachycardia (signs of significant blood loss). A positive pregnancy test with bleeding and pelvic pain raises concern for ectopic pregnancy, a surgical emergency affecting approximately 2% of all pregnancies [19]. Postmenopausal bleeding (any bleeding occurring 12 or more months after the final menstrual period) requires evaluation within 2 weeks because endometrial cancer is the cause in approximately 9% of postmenopausal bleeding cases [20].

Heavy spotting soaking through a pad per hour for more than two consecutive hours, bleeding with fever, and new-onset bleeding in a patient on anticoagulants all warrant prompt medical contact. When in doubt, call your provider's office. A brief phone triage can determine whether the situation requires imaging that day or can wait for a scheduled appointment.

Building Your Personal Action Plan

Start with documentation. Track the timing, volume, and associated symptoms (pain, discharge, fever) of each spotting episode for at least two full cycles using a period-tracking app or written log. This information is more useful to your provider than a vague report of "some spotting."

Schedule a visit with your gynecologist or primary care provider. Bring your bleeding diary. Expect the provider to perform a pelvic exam and order the baseline lab panel described above (beta-hCG, CBC with ferritin, TSH, prolactin). If you have a personal or family history of easy bruising, heavy bleeding since menarche, or bleeding after dental procedures, mention this explicitly so coagulation studies are included.

After labs and initial ultrasound, your provider will place your spotting into one of the PALM-COEIN categories and discuss treatment options. Ask specifically: "Do I need an endometrial biopsy?" Women over 45 with AUB should always receive one. Women aged 35 to 44 with risk factors should receive one. If your provider does not offer it and you meet these criteria, request it [6].

Follow up at the interval your provider recommends, typically 3 months after starting treatment. If spotting persists despite first-line therapy, the next steps usually include SIS or hysteroscopy to evaluate for structural lesions missed on standard ultrasound. Persistent unexplained bleeding after a negative workup may warrant referral to a reproductive endocrinologist or gynecologic subspecialist. The Endocrine Society clinical practice guidelines provide additional algorithms for evaluating menstrual disturbances in the setting of suspected PCOS or hypothalamic amenorrhea [10].